NCT07239544

Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines

Generation of Tumor-reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: The First Affiliated Hospital of Soochow University · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Tumor-reactive T cells are generated based on the tumor full antigen nanovaccine and the tumor-reactive T cells are reinjected for autologous therapy to provide the optimal treatment plan for clinical patients.

Detailed description

To evaluate the anti-tumor effect of tumor-reactive T cells in human-derived 3D lung cancer organoids, and analyze the in vivo migration location, tumor infiltration characteristics and survival kinetics of reinjected tumor-reactive T cells to clarify their role in biotherapy and transformation potential.

Conditions

• Lung Cancer (NSCLC)

Interventions

Type	Name	Description
OTHER	observational study	observational study:Evaluate the broad-spectrum coverage of xenogeneic hybrid lung cancer antigens (including patient tissues and cell lines), and develop a universal whole-cell antigen nanodelivery system to replace autologous tumor-derived preparation

Timeline

• Start date: 2025-07-10
• Primary completion: 2026-07-10
• Completion: 2026-07-10
• First posted: 2025-11-20
• Last updated: 2025-11-20

Locations

1 site across 1 country: China